

----- PRESS RELEASE -----

Herpen, The Netherlands and Graz, Austria, June 19, 2023

Orexa collaborates with CRO QPS for Phase 2a Trial in the Prevention of Post-Operative Ileus

HERPEN, THE NETHERLANDS and GRAZ, AUSTRIA - Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, has selected Clinical Research Organization QPS to conduct its Phase 2a clinical trial in the prevention of postoperative ileus. The trial will investigate whether patients who undergo major abdominal surgery will develop less gastrointestinal disturbances and will recover more quickly.

Study 2022-503113-31-00-IN-002 (EudraCT number) is a multi-center, randomized, double-blind, placebo-controlled pilot study to investigate the efficacy of Orexa's lead compound ORE-001. It will enroll 100 to 120 female patients who undergo gynecologic surgery requiring longitudinal laparotomy. The study will run at multiple centers in Germany with lead investigator Prof. Alexander Mustae from Universitätsklinikum Bonn (UKB).

"This is a major milestone for a company like Orexa to start its first clinical Phase 2a study," says Prof. Ard Peeters. He continues: "Finally we will be able to test our drug in patients. This first study is in a group where we can possibly prevent a so-called postoperative ileus. This is a serious complication, which affects up to 50% of patients in several patient groups and leads to patients being unable to eat and therefore recovering more slowly, resulting in prolonged hospitalization."

"QPS is honored to partner with Orexa to conduct its first clinical Phase 2a study for their important lead compound, ORE-001", says Kevin Vernarec, QPS (SVP and Global Head of Late Phase Clinical Development). "We expect the majority of patients within this study to be ovarian cancer patients. This is the 8th most common cancer in women and there is a clear need for therapies to address postoperative ileus, a common sequela of advanced abdominal or pelvic cancers, such as ovarian cancer. We are thrilled to be a part of advancing available treatments in this area".

About Orexa:

Orexa is developing a drug that increases food intake. The markets where increased food intake can lead to substantial health benefits are large. Orexa focuses primarily on the recovery of patients who have undergone surgery, anorexia patients and people with malnutrition (sarcopenia / cachexia). The company is founded in 2016 and is based in Herpen (North Brabant), The Netherlands.

For more information, see www.orexa.eu.